Skip to Content

Genfit SA GNFTF

Morningstar Rating
$5.53 +0.40 (7.80%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

GNFTF is trading at a 471% premium.
Price
$5.55
Fair Value
$9.43
Uncertainty
Very High
1-Star Price
$34.79
5-Star Price
$5.64
Economic Moat
Jnnw
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GNFTF is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$5.13
Day Range
$5.505.53
52-Week Range
$2.955.53
Bid/Ask
$0.01 / $83,204.73
Market Cap
$275.73 Mil
Volume/Avg
1,653 / 892

Key Statistics

Price/Earnings (Normalized)
Price/Sales
8.89
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
159

Comparables

Valuation

Metric
GNFTF
IVA
AELIS
Price/Earnings (Normalized)
Price/Book Value
3.6711.98
Price/Sales
8.896.7517.10
Price/Cash Flow
Price/Earnings
GNFTF
IVA
AELIS

Financial Strength

Metric
GNFTF
IVA
AELIS
Quick Ratio
2.870.852.38
Current Ratio
2.940.962.48
Interest Coverage
−5.54−20.40−33.55
Quick Ratio
GNFTF
IVA
AELIS

Profitability

Metric
GNFTF
IVA
AELIS
Return on Assets (Normalized)
−15.01%−125.09%−14.59%
Return on Equity (Normalized)
−36.95%−5,550.40%−28.94%
Return on Invested Capital (Normalized)
−17.70%−275.68%−24.22%
Return on Assets
GNFTF
IVA
AELIS
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
VnjhyftjnGqcrr$636.2 Bil
Vertex Pharmaceuticals Inc
VRTX
TgdsljrfWytbmtf$126.1 Bil
Regeneron Pharmaceuticals Inc
REGN
QxcthlnmdSdzsqr$121.2 Bil
Moderna Inc
MRNA
NdblyxyMkq$46.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
NjwjjpvllFktpvvf$33.0 Bil
argenx SE ADR
ARGX
BkkwyhjtnDvg$27.9 Bil
BioNTech SE ADR
BNTX
ZvtxjzzvDxs$20.5 Bil
Biomarin Pharmaceutical Inc
BMRN
PgxpjxhfHfzbmq$16.1 Bil
United Therapeutics Corp
UTHR
WcwgjkhgNncfb$14.3 Bil
Incyte Corp
INCY
BqkcmpppCgbhpm$12.5 Bil

Sponsor Center